ArticleBlood2018
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.Molecular cancer therapeutics · 2025Trial
- Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma.Blood advances · 2026Article
- Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.American journal of blood research · 2026Review
- NMRK2 leads to the depletion of CD8Oncogene · 2025Article
- Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy.EJNMMI radiopharmacy and chemistry · 2024Article
- CD38 as theranostic target in oncology.Journal of translational medicine · 2024Review
- Radioimmunotheragnosis in Cancer Research.Cancers · 2024Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management.Theranostics · 2024Review
- Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors.Research (Washington, D.C.) · 2023Article
- Pretargeting: A Path Forward for Radioimmunotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery.International journal of molecular sciences · 2022Review
- Review
- Radiotheranostic Agents in Hematological Malignancies.Frontiers in immunology · 2022Review
- An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies.Blood advances · 2021Article
- Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.Science translational medicine · 2021Article
- A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.Journal of hematology & oncology · 2021Article
- Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.Bioconjugate chemistry · 2021Article
- Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 andMolecular cancer therapeutics · 2020Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of multiple myeloma (MM) and other B-cell malignancies, for which we developed an anti-CD38-bispecific fusion protein that eliminates endogenous biotin interference and immunogenic elements. In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood clearance and tumor targeting. Dosimetry calculations showed a tumor-absorbed dose of 43.8 Gy per millicurie injected dose of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.